Metagenomic Innovations from Collection to Action

Metagenomic Innovations from Collection to Action

Infectious diseases claim over 18 million lives globally each year.*

A number exacerbated by the low sensitivity and yield of traditional diagnostic methods.

Current pathogen detection methods can fail to provide accurate and timely microbial data, essential for understanding microbial dynamics, developing targeted therapies, and identifying emerging threats.

A more sensitive and comprehensive microbiological test is needed to improve research capabilities and clinical outcomes.

*WHO 2023 data adjusted to include COVID deaths.

Realizing the Promise of Metagenomic Next-Generation Sequencing (mNGS)

Only mNGS can:

Identifying known and novel
pathogens simultaneously

Detect low-abundance
microorganisms

Profile antimicrobial
resistance genes

Offer insights into microbial
functions and host responses

Despite its promise, mNGS presents challenges because microbes constitute only a tiny fraction of the genomic material in a sample.

Host, reagent, and environmental contaminants overwhelm microbial signals, leading to decreased detection sensitivity, increased workflow complexities, and higher costs.

That’s why we develop the products that systematically remove the barriers to mNGS adoption from specimen collection to definitive action, empowering you to quickly and easily implement mNGS.

Infectious diseases claim over 18 million lives globally each year.*

A more sensitive and comprehensive microbiological test is needed to improve research capabilities and clinical outcomes.

Realizing the Promise of Metagenomic Next-Generation Sequencing (mNGS)

Only mNGS can:

Identifying known and novel pathogens simultaneously

Detect low-abundance microorganisms

Profile antimicrobial resistance genes

Offer insights into microbial functions and host responses

Despite its promise, mNGS presents challenges because microbes constitute only a tiny fraction of the genomic material in a sample.

Host, reagent, and environmental contaminants overwhelm microbial signals, leading to decreased detection sensitivity, increased workflow complexities, and higher costs.

That’s why we develop the products that systematically remove the barriers to mNGS adoption from specimen collection to definitive action, empowering you to quickly and easily implement mNGS.

Improving Research, Diagnosis, Treatment and Surveillance

Testimonial with Read More/Less

Bora Ergin

PhD, R&D, INTERGEN Genetics and Rare Diseases Diagnosis Research & Application Center

"Because the patients we serve have rare and undiagnosed diseases, we are committed to utilizing the most advanced technologies available. My responsibility is to identify, evaluate, and integrate new testing modalities into our diagnostic repertoire. There is a pressing need for more comprehensive infectious disease testing, and Micronbrane Medical’s products are crucial in enabling us to apply mNGS to quickly and accurately identify causal pathogens, ultimately enhancing outcomes for all our patients."

Testimonial with Read More/Less

Joanne Watkins

BSc MSc CSci MIBMS, Deputy Head of Pathogen Genomics Unit, Public Health Wales

"As a laboratory within Public Health Wales, we use NGS to sequence hundreds of samples a month. For some cultured organisms received, we were not able to get sequencing results for about 30% of those samples due to the high representation of the host genome. However, after using the Devin™ Host Depletion filters, the sequencing failure rate has dropped by two thirds. Given the results, we are looking at other Micronbrane Medical products to make further improvements to service for the benefit of the people of Wales."

Testimonial with Read More/Less

Victor Nizet

"Precise and reliable bacterial identification is key to our basic and translational research in host-pathogen interactions and infectious diseases drug discovery, including work with human samples, tissue culture systems, and animal models. Metagenomic NGS is a powerful emerging tool for these objectives, including new work with probiotics and microbial communities. Micronbrane Medical's PaRTI-Seq assay piqued our interest because of its ability to minimize contamination and enhance signal quality. We are exploring its application to specific microbial genes or pathways involved in infection and antibiotic resistance to support our efforts to develop targeted therapies against multidrug-resistant pathogens."

Testimonial with Read More/Less

Bora Ergin

PhD, R&D, INTERGEN Genetics and Rare Diseases Diagnosis Research & Application Center

“Because the patients we serve have rare and undiagnosed diseases, we are committed to utilizing the most advanced technologies available. My responsibility is to identify, evaluate, and integrate new testing modalities into our diagnostic repertoire. There is a pressing need for more comprehensive infectious disease testing, and Micronbrane Medical’s products are crucial in enabling us to apply mNGS to quickly and accurately identify causal pathogens, ultimately enhancing outcomes for all our patients.”

Testimonial with Read More/Less

Joanne Watkins

BSc MSc CSci MIBMS, Deputy Head of Pathogen Genomics Unit, Public Health Wales

“As a laboratory within Public Health Wales, we use NGS to sequence hundreds of samples a month. For some cultured organisms received, we were not able to get sequencing results for about 30% of those samples due to the high representation of the host genome. However, after using the Devin™ Host Depletion filters, the sequencing failure rate has dropped by two thirds. Given the results, we are looking at other Micronbrane Medical products to make further improvements to service for the benefit of the people of Wales.”

Testimonial with Read More/Less

Victor Nizet

“Precise and reliable bacterial identification is key to our basic and translational research in host-pathogen interactions and infectious diseases drug discovery, including work with human samples, tissue culture systems, and animal models. Metagenomic NGS is a powerful emerging tool for these objectives, including new work with probiotics and microbial communities. Micronbrane Medical’s PaRTI-Seq assay piqued our interest because of its ability to minimize contamination and enhance signal quality. We are exploring its application to specific microbial genes or pathways involved in infection and antibiotic resistance to support our efforts to develop targeted therapies against multidrug-resistant pathogens.”